Shots:

• Eli Lilly launches Reyvow C-V 50/100/200mg- indicated for the acute treatment of migraine with/without aura & will be available in US pharmacies in the next few days
• The efficacy of the therapy is evaluated in SAMURAI and SPARTAN studies assessing Reyvow vs PBO in 4439 patients with migraine- results demonstrated that patients achieved fast and complete elimination of migraine pain @2hrs. (28-39% vs 15% & 21%)- patients achieved MBS @2hrs. (41-49% vs 30% & 33%)
• Reyvow is a 5-HT1F receptor agonist- the first and only FDA-approved ditan- designed to act both centrally and peripherally and has received approval in Oct’2019

Click here ­to­ read full press release/ article 

Ref: Eli Lilly | Image: Eli Lilly